|
|||||
|
|

Consumer products giant Clorox (NYSE:CLX) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 18.9% year on year to $1.43 billion. Its non-GAAP profit of $0.85 per share was 9.2% above analysts’ consensus estimates.
Is now the time to buy CLX? Find out in our full research report (it’s free for active Edge members).
Clorox’s third quarter results were received positively by the market, as the company beat Wall Street’s revenue and non-GAAP profit expectations despite a sharp year-over-year sales decline. Management attributed the performance to operational progress following the U.S. launch of a new enterprise resource planning (ERP) system, which strengthened Clorox’s digital infrastructure but contributed to short-term disruptions. CEO Linda Rendle emphasized that, while the ERP transition presented challenges, its successful implementation has already begun delivering operational benefits and will support future efficiency gains.
For the remainder of the year, Clorox’s outlook is anchored by an expectation of gradual category stabilization and renewed innovation across its major brands. Management highlighted that the company’s demand creation plan, supported by increased advertising and targeted promotional activities, is designed to regain market share and drive a return to organic sales growth in the back half. CFO Luc Bellet noted, “We feel good about our ability to meet our gross margin outlook,” while Rendle pointed to an innovation pipeline intended to “create years and years of value” for consumers, especially as household penetration for core brands remains robust.
Management attributed the quarter’s results to ERP implementation challenges, evolving consumer value-seeking behaviors, and a more competitive promotional environment.
Clorox’s guidance for the next few quarters is shaped by category stabilization, a strong innovation pipeline, and ongoing efforts to manage promotional pressures and costs.
Looking ahead, our analysts will monitor (1) the pace of market share recovery as new product innovations roll out, (2) signs of gross margin expansion from ERP-enabled efficiencies and disciplined marketing spend, and (3) stabilization in core categories such as trash bags and cat litter, where promotional pressures remain elevated. Execution on brand reinvestment and private label defense will also be key indicators of strategic progress.
Clorox currently trades at $112.90, up from $109.01 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free for active Edge members).
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Dec-15 | |
| Dec-13 | |
| Dec-12 | |
| Dec-12 | |
| Dec-11 | |
| Dec-11 | |
| Dec-03 | |
| Dec-02 | |
| Nov-30 | |
| Nov-24 | |
| Nov-20 | |
| Nov-19 | |
| Nov-19 | |
| Nov-18 | |
| Nov-17 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite